Therefore, this treatment synergizes with anti-PD-1 immunotherapy and other immune checkpoint inhibitors to enhance CD8+ T-cell infiltration, offering protection against cachexia in a colon cancer mouse model.315. Here, CD8A is linked to Cachexia.